Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Large Increase in Short Interest


Share on StockTwits

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 2,750,000 shares, a growth of 24.4% from the March 31st total of 2,210,000 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily volume of 996,300 shares, the days-to-cover ratio is presently 2.8 days.

REGN stock traded down $3.44 during mid-day trading on Tuesday, reaching $485.18. The company had a trading volume of 745,603 shares, compared to its average volume of 977,554. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.89 and a quick ratio of 3.12. The company has a market capitalization of $51.98 billion, a PE ratio of 17.73, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. The firm has a 50 day moving average of $482.38 and a 200 day moving average of $503.31. Regeneron Pharmaceuticals has a 12 month low of $441.00 and a 12 month high of $664.64.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, February 4th. The biopharmaceutical company reported $9.53 EPS for the quarter, topping the Zacks’ consensus estimate of $7.11 by $2.42. Regeneron Pharmaceuticals had a net margin of 38.28% and a return on equity of 28.97%. The business had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.40 billion. During the same period in the prior year, the firm earned $7.50 EPS. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals will post 27.23 EPS for the current year.

Several brokerages have recently commented on REGN. Canaccord Genuity restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 13th. FIX upgraded Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $635.00 to $575.00 in a research note on Friday, January 8th. Robert W. Baird reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 13th. Cowen cut their target price on shares of Regeneron Pharmaceuticals from $684.00 to $565.00 and set an “outperform” rating for the company in a research note on Monday, February 8th. Finally, Credit Suisse Group increased their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $760.00 and gave the company an “outperform” rating in a report on Monday, March 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Buy” and an average price target of $644.17.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alliancebernstein L.P. boosted its stake in shares of Regeneron Pharmaceuticals by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,763,344 shares of the biopharmaceutical company’s stock valued at $851,889,000 after purchasing an additional 208,936 shares in the last quarter. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $506,839,000. Bank of New York Mellon Corp boosted its stake in shares of Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Bank of New York Mellon Corp now owns 828,264 shares of the biopharmaceutical company’s stock valued at $400,141,000 after purchasing an additional 8,138 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 8.7% during the fourth quarter. UBS Asset Management Americas Inc. now owns 643,442 shares of the biopharmaceutical company’s stock valued at $310,853,000 after purchasing an additional 51,243 shares in the last quarter. Finally, Swiss National Bank boosted its stake in shares of Regeneron Pharmaceuticals by 4.6% during the fourth quarter. Swiss National Bank now owns 596,122 shares of the biopharmaceutical company’s stock valued at $287,992,000 after purchasing an additional 26,000 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Trading on Margin

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.